Sitabem Tablet 50/850 Milligrams
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Aprogen Pharmaceuticals, Co., Ltd.
MFDS item code 202200225 · Approved 2022.01.12
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to help effectively control blood sugar levels in patients with type 2 diabetes. It can be administered when sufficient blood glucose control is not attainable through monotherapy or when blood glucose control is inadequate with either metformin or sitagliptin alone. It also serves to enhance treatment efficacy when combined with metformin and sulfonylureas, or thiazolidinediones, when blood glucose control has not improved. If blood sugar control is still insufficient after combination therapy with insulin and metformin, this medication can be used in conjunction with insulin. It shows better effects when used along with dietary and exercise therapy. It is utilized in various situations to enhance blood glucose control.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each ingredient: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine is determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may affect blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Because this medicine contains metformin, it should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Do not administer to the following patients).
This drug contains both sitagliptin and metformin and is used for the treatment of type 2 diabetes. During the use of this drug, severe allergic reactions may occur; therefore, if a rash, hives, shortness of breath, or swelling of the face or neck occurs, discontinue immediately and consult a doctor. If symptoms of acute pancreatitis, such as abdominal pain, nausea, or vomiting, appear, discontinue use and seek medical attention. This medication should not be given to patients with poor kidney function, severe infections, dehydration, acute heart failure, or acute myocardial infarction. Temporary discontinuation of this medication is necessary before and after tests involving iodine-based contrast agents, and resuming should only occur after confirming normal kidney function. Pregnant women or those who may become pregnant, as well as breastfeeding women, should not take this medication. Caution is needed due to the risk of hypoglycemia, especially in cases of irregular meals, intense exercise, or concurrent use with other hypoglycemic agents. Regular kidney function and blood tests should be conducted during treatment, especially for the elderly, who need to be more vigilant about changes in kidney function. Excessive alcohol consumption should be avoided while taking this medication, as it may increase the risk of lactic acidosis. If scheduled for surgery or in cases of severe infection or trauma, this medication should be temporarily discontinued and resumed after recovery. In case of an overdose, seek medical attention immediately for appropriate treatment, as some components may be removed through dialysis. Severe joint pain or skin blisters should be reported to a doctor immediately, and medication should be halted if such symptoms occur. This medication may cause gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain) and headache, as well as upper respiratory infections; consultation with a doctor is essential if symptoms worsen. If hypoglycemic symptoms arise, it is crucial to consume fast-acting carbohydrates or glucose immediately, and if symptoms persist, notify healthcare personnel. Patients should monitor their blood glucose and symptoms regularly, and consult healthcare personnel promptly if there are any abnormal signs.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that allows air circulation, at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness for a longer duration.
Pink, oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Aprogen Pharmaceuticals, Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.